Home
About
Share This
Set as HomepageVimpat
VIMPAT PI LabelingText v
HIGHLIGHTSOFPRESCRIBINGINFORMATION These highlightsdo not includeallthe informationneeded to use VIMPAT ® safely and effectively. SeefullprescribinginformationforVIMPAT.
Patient Assistance Program Patient (or Legal Guardian ...
Please see Keppra.comforfullprescri bi nginformation. • Vimpat ® (lacosamide) tablets, C-V Available strengths: 50 mg, 100 mg, 15 0mg, and 200mg Max daily dose: 400 mg Vimpat ® tablets are indicated as adjunctive therapy in the treatment of partial onset seizures in patients with epilepsy who are 17 ...
Vimpat Medication Guide 2009
Medication Guide VIMPAT ( VIM-păt. ) lacosamide VIMPAT and Suicidal Thoughts or Actions Read this Medication Guide before you start taking VIMPAT and each time you get a refill.
Pharmacy Medical Necessity Guidelines: Vimpat® (lacosamide ...
Pharmacy Medical Necessity Guidelines Vimpat ® (lacosamide) tablets and solution 1 of 3 Document ID#: 2139018 Subject: Vimpat (lacosamide) tablets and solution Effective Date: September 13, 2011 Clinical Documentation and Prior Authorization Required √ Type of Review — Case Management Not ...
Vimpat (Lacosamide) - What is Vimpat (Lacosamide)?
Comprehensive Epilepsy Center (734) 936-9020 - 1 - Vimpat (Lacosamide) What is Vimpat (Lacosamide)? Vimpat is an anti-epileptic drug that was FDA approved to treat patients with
Vimpat (lacosamide) Tablets and Injection Label
Approved Labeling Text - NDA 22-253 and 22-254 dated October 28, 2008 Vimpat (lacosamide) Tablets and Injection Page 1 of 29 Vimpat (lacosamide) Tablets and Injection Label
Canadian Expert Drug Advisory Committee Final Recommendation ...
(Vimpat – UCB Canada Inc.) Indication: Epilepsy, Partial-Onset Seizures Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that Vimpat, which is
Questions and answers on the recall of Vimpat 15mg/ml syrup ...
7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa. eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011.
VIMPAT Fact Sheet
Page 1 of 3 Source: UCB June 2010 Fact Sheet Vimpat ® (lacosamide): An Antiepileptic Drug for Add-on Therapy with a Novel Mechanism of Action • Vimpat is indicated as add-on therapy for the treatment of partial-onset seizures, a common seizure type in epilepsy, in people 17 years and older.
Approval Letter: Vimpat
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 NDA APPROVAL NDA 22-253 NDA 22-254 Schwarz Biosciences, Inc. Attention: Alan Blumberg Senior Director, US Regulatory Affairs P.O. Box 110167 Research Triangle Park, NC 27709 Dear Mr ...
